The Discounted Cash Flow (DCF) valuation of Esperion Therapeutics Inc (ESPR) is 7.16 USD. With the latest stock price at 2.50 USD, the upside of Esperion Therapeutics Inc based on DCF is 185.7%.
Based on the latest price of 2.50 USD and our DCF valuation, Esperion Therapeutics Inc (ESPR) is a buy. buying ESPR stocks now will result in a potential gain of 185.7%.
| Range | Selected | |
| WACC / Discount Rate | 5.9% - 7.7% | 6.8% |
| Long-term Growth Rate | 2.0% - 4.0% | 3.0% |
| Fair Price | 4.42 - 15.45 | 7.16 |
| Upside | 76.6% - 516.7% | 185.7% |